3European heart rhythm association ,heart rhythm society, zipes DP, et al. ACC/AHA/ESC2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. J Am Coll Cardiol, 2006,48(5):e247-e346.
4Eikelboom JW,Hirsh J,Weitz JI,et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events[J]. Circulation, 2002,105(14):1650-5.
5Grimm W,Christ M,Bach J,et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy:results of the Mar- burg[J]. Cardiomyopathy Study Circulation,2003,108(23):2883-91.
6Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patiens with hypertrophic cardiomyopathy[J]. Circ J,2010,74(11):2271-82.
7Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy[J]. Circulation,2010,121 (3):445-56.
8Gersh BJ,Maron BJ,Bonow RO,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines[J]. Circulation,2011,124(24):e783-e831.
9Barahona-Dussault C,Benito B,Campuzano O,et al. Role of genetictesting in arrhythmogenic right ventricular cardiomyopathy/ dysplasia[J]. Clin Genet,2010,77(1):37-48.
10De Bruin ML,Pettersson M,Meyboom RH,et al. Anti-HERG activity and the risk ofdrug, inducedarrhythmias and sudden death[J]. Eur Heart J,2005,26(6):590-7.
